Barriers to SARS-CoV-2 Testing among U.S. Employers in the COVID-19 Pandemic: A Qualitative Analysis Conducted January through April 2021

Int J Environ Res Public Health. 2022 Sep 19;19(18):11805. doi: 10.3390/ijerph191811805.

Abstract

During the first year of the COVID-19 pandemic, U.S. companies were seeking ways to support their employees to return to the workplace. Nonetheless, the development of strategies to support the access, use, and interpretation of SARS-CoV-2 testing was challenging. In the present study, we explore, from the perspective of owners and company leadership, the barriers to SARS-CoV-2 testing among U.S. companies. Key informant interviews with company representatives were conducted during January-April 2021 about SARS-CoV-2 testing. A pre-interview survey assessed respondent socio-demographic and organizational characteristics. Interview sessions were transcribed, coded, and analyzed using MaxQDA. A total of twenty interviews were completed with at least two interviews conducted in each major U.S. industry sector. Ninety percent of participants represented companies in business >10 years, comprising both small and large workforces. Using a grounded theory approach, six themes emerged: (1) access to and knowledge of SARS-CoV-2 tests; (2) strategies for symptomatic and asymptomatic testing of workers; (3) type/availability of personal protective equipment to mitigate coronavirus exposures; (4) return-to-work policies; (5) guidance and communication of SARS-CoV-2 Testing; and (6) use of contact tracing and SARS-CoV-2 vaccination. Various modifiable and non-modifiable challenges for SARS-CoV-2 testing among U.S. companies were identified and can inform work-related SARS-CoV-2 testing strategies.

Keywords: COVID-19; SARS-CoV-2; barriers; companies; organizations; testing.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • COVID-19 Testing
  • COVID-19 Vaccines
  • COVID-19* / diagnosis
  • COVID-19* / epidemiology
  • Humans
  • Pandemics
  • SARS-CoV-2*

Substances

  • COVID-19 Vaccines

Grants and funding

Financial support for this study is from CDC/NIOSH Intergovernmental Personnel Act (IPA) agreements for the effort of authors A.J.C.-M., C.P., C.K.B., J.L.L., K.M., D.N., E.S. and M.S.T.